ABCann heißt jetzt VIVO Cannabis
eröffnet am 08.10.18 15:59:14 von
neuester Beitrag 22.12.22 14:57:01 von
neuester Beitrag 22.12.22 14:57:01 von
Beiträge: 361
ID: 1.290.066
ID: 1.290.066
Aufrufe heute: 0
Gesamt: 25.438
Gesamt: 25.438
Aktive User: 0
ISIN: CA92845J1049 · WKN: A2JR3J
0,0120
EUR
-22,08 %
-0,0034 EUR
Letzter Kurs 04.04.23 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,000 | +25,00 | |
| 6,0000 | +25,00 | |
| 0,7113 | +21,90 | |
| 0,6400 | +18,52 | |
| 1,1100 | +15,70 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8410 | -17,06 | |
| 9,7200 | -19,60 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Beitrag zu dieser Diskussion schreiben
FeedbackVIVO Cannabis Announces Fourth Quarter 2021 Results
https://www.newsfilecorp.com/release/118743/VIVO-Cannabis-An…Net revenue for Q4 2021 was $6.9 million; Net revenue for 2021 was $25 million.
In February 2021, closed a $7.2 million equity raise to help fund VIVO's growth
In July 2021, the Company elected a new Board of Directors, announced the appointment of Ray Laflamme as CEO and Chairman of the Board and later welcomed the Former President of McCain Foods Canada and CEO of Zenabis Global, and Former CFO of Cronos Group, to the Board of Directors.
In July 2021, announced that its EU-GMP licensed subsidiary, Beacon Medical Germany GmbH, received its first import permit from Germany's BfArM, the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte), allowing for the import of Canadian grown dried flower medical cannabis from the Company's EU-GMP-certified Napanee, Ontario site, into Europe.
In December 2021, recorded first significant revenues of Canadian produced EU-GMP product by VIVO's German business
In mid 2021 the Company refined its strategy and is now focused primarily on medical cannabis
The Company continues to have market leadership in Australia and leveraged its Canadian knowledge base to accelerate product efficacy, cannabis medical information sharing, and sales growth
With the Company's EU-GMP certification, it is now in a position to repeat its Australian success in Germany and in other global markets, all of which are exclusively medically focused
Over 350% year-over-year sales growth in Australia
VIVO Cannabis(TM) Announces Third Quarter 2021 Results
https://www.newsfilecorp.com/release/103717/VIVO-CannabisTM-… Trading Spotlight
VIVO Cannabis(TM) Completes First Shipment of EU-GMP Medical Grade Cannabis to Beacon Medical Germany GmbH
https://www.newsfilecorp.com/release/100411/ VIVO Cannabis(TM) Adds Craft Licensed Producer, Delta 9 to Online Medical Marketplace
https://www.newsfilecorp.com/release/98774/VIVO-CannabisTM-A…
7Mio weniger Umsatz….in q2 2021 zu q2 2020….
https://www.marketscreener.com/quote/stock/VIVO-CANNABIS-INC…
https://www.marketscreener.com/quote/stock/VIVO-CANNABIS-INC…
Gutes Zeichen oder schlechtes Zeichen? Laflamme ist immerhin Vivo's 2. größter Anteilseigner.
Durchsuchen
